HOME >> BIOLOGY >> NEWS
New bipolar survey: Patients' satisfaction influenced

Vienna, June 29th 2005 Preliminary results from a large-scale global study of people living with bipolar disorder,1 presented today at the World Congress of Biological Psychiatry (WCBP), found that patient satisfaction with treatment is achieved through combining broad-based efficacy with a favourable tolerability profile.

The Thinking Ahead Survey,1 included 687 bipolar patients from seven countries (UK, US, Germany, Italy, Canada, Spain and Greece). These preliminary results indicate that:

  • 88% of respondents said drug treatment satisfaction is largely influenced by how effective it is, followed then by patients experiencing few or manageable side effects (77%)

  • 79% of respondents believe that a successful treatment would be one which leads to significant quality of life changes in terms of increased functionality and improved lifestyle

Bipolar disorder, also known as manic-depressive illness, is a severe biological disorder that affects approximately 3-4% of the adult population.5,6 More than half of those with bipolar disorder stop taking their medication at some point during their illness, subjecting themselves to a high risk of relapse and an increased risk of suicide.7

"As someone who lives with bipolar disorder I need a treatment which can control the manic symptoms but also treat the more disabling depressive symptoms," comments Michael Grinter, SEROQUEL patient and Thinking Ahead Taskforce member. "The treatment that I am currently taking, SEROQUEL, has brought an enormous benefit to my life in terms of controlling both poles of my mood and has enabled me to return to work and live a fully functioning life. It has provided me with the confidence to enjoy each day again."

Recently-published SEROQUEL (quetiapine) data in the Journal of Current Medical Research and Opinion confirm SEROQUEL's efficacy and tolerability in the treatment of bipolar mania symp
'"/>

Contact: Lisa O'Sullivan
lisa.o'sullivan@shirehealthinternational.com
44-207-108-6515
Shire Health International
29-Jun-2005


Page: 1 2 3

Related biology news :

1. New databases put wings on search for bipolar risk genes
2. $9M grant awarded to University of Cincinnati for bipolar disorder research
3. Genetic roots of bipolar disorder revealed by first genome-wide study of illness
4. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
5. Gene controlling circadian rhythms may be involved in onset of bipolar disorder
6. Extreme irritability -- is it childhood bipolar disorder?
7. Fear circuit flares as bipolar youth misread faces
8. Clock molecules sensitivity to lithium sheds light on bipolar disorder
9. Link suggested between regions on two chromosomes and bipolar disorder
10. Research zeros in on bipolar disorder genes, link with thyroid condition
11. Beyond lithium for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New bipolar survey Patients satisfaction influenced

(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
(Date:4/27/2015)... , 27 avril 2015 ... spécialisée dans le développement d,une nouvelle ... les infections bactériennes polypharmacorésistantes potentiellement mortelles, ... données prouvant les promesses de son ... la lutte contre la résistance aux ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... an exhibitor at the Texas Commission on Environmental ... 5-6 in Austin, Texas. , The company will ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6SynGen Inc. Expands Its Management Team 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
Cached News: